
The new EU proposal to revamp its pharmaceutical regulations. The main aim is to give people a better and more affordable access to medicines.
From what I can see, there are mixed feelings about the proposal. On one hand, consumer groups and civil society organizations are applauding the EU’s efforts to make medicines more accessible. On the other hand, the pharmaceutical industry is a bit skeptical.
So, what’s in the proposal? Well, the EU is looking to shorten the period in which pharmaceutical companies can sell their medicines without competition from 10 years to just 8 years. They’re also working towards closing the gap in access to medicines among different EU member states.
It’s interesting to see how this will all play out. What are your thoughts on the EU Pharmaceutical Regulations Proposal?
Recent Posts

Clinical Trial Monitoring: Insights from Q1 2026 EU/EEA Report

Novartis Oncology Advancements: Key Trial Findings and Market Implications
